Delcath Systems

DELCATH SYSTEMS INC

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Nvidia shutterstock_2567997995

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANNA

BLCO

DCTH

EFSI

HLMN

MAGN

NVDA

OMER

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

movers image

$BTC

CGEM

DSGN

MSTR

NPCE

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AIRE

BAOS

BREA

CREV

HOUR

LICN

LKCO

MGIH

SOBR

SPRC

SVRE

TCTM

ZCAR

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket

Delcath Systems Inc

Press Releases

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Management

Beta Bionics Announces Board Appointment of Gerard Michel

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

BBNX

AngioDynamics

Artivion

AtriCure

Axogen

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

ClearPoint Neuro

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

NeuroPace

Orthofix Medical

Outset Medical

Omnicell

Pulse Biosciences

Senseonics Holdings

SI-BONE

Semler Scientific

SANUWAVE Health

Surmodics

Neuronetics

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Varex Imaging

HC Wainwright & Co.

Craig-Hallum

Canaccord Genuity

Stephens & Co.

Comments

Delcath Systems

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell